Warmly Welcome | Nobel Prize Nominee Professor Colin Masters visit Qankorey Life Science R&D Center
Visits:
2024-09-20
On the morning of 18 September 2024, Colin L Masters, head of the FLOREY Institute at the University of Melbourne and founder of the AIBL, one of the world's largest dementia research groups, came to Qankorey Life Sciences R&D center, located in the Yuhua economic development zone, for field visits and in-depth research. Gu Baijun, chief scientist of Qankorey, said that a drug targeting Alzheimer's disease will enter the market at the end of next year at the earliest.
Alzheimer's disease, commonly known as dementia, occurs mostly in old age. With the arrival of an ageing society, its incidence rate is rising. Currently, there are about 50 million patients worldwide, of which China accounts for a quarter, ranking first in the world in terms of the number of patients and the growth rate of incidence.
"Because the early symptoms of Alzheimer's disease are often overlooked, many patients are already in the middle and late stages of the disease when they are diagnosed. Therefore, early screening and intervention for the disease is particularly important." According to Zhengqian Dai, CEO of Hunan Qankorey Biotechnology Co.,Ltd, said that Qankorey has been providing overall solutions for the prevention, screening, diagnosis and treatment of Alzheimer's disease, and has maintained a long-term good cooperative relationship with the FLOREY Institute and AIBL organization team. And the world's first Alzheimer's disease early risk screening reagent-one step dementia risk test kit is jointly developed by FLOREY Institute and Qankorey.
As the R&D and innovation carrier of Qankorey, Qankorey Life Science R&D Centre is equipped with international high-end laboratory equipment, with 10,000-class laboratory, 100,000-class professional medical device production site of nearly 2,000 square meters, the company's R&D Centre currently has more than 50 core R & D personnel with high degrees such as doctor and master, , and has strong independent research and development and innovation capabilities. We are recruiting talents worldwide to ensure the smooth development of scientific research tasks.
"Our existing core technologies have independent intellectual property rights and PCT invention patent protection, and we have applied for more than 50 patents, including 9 PCT international patents." Baijun Gu said that in addition to Alzheimer's disease early risk screening reagents, Alzheimer's disease early intervention of proprietary Chinese medicine has completed the transformation of results, plans to be registered in Hong Kong in November (drug license number), the fastest will officially enter the market by the end of next year.
It is worth mentioning that Colin L Masters, who has been nominated for the Nobel Prize in Medicine for many times and is also the chief consultant of Qankorey, highly evaluated the business environment of Yuhua Economic development zone and showed great interest in building a global research and development center for Alzheimer's disease prevention and treatment. He said that he would share this visit with his team, plan new directions and jointly explore more cooperation opportunities together.
RELATED INFORMATION
Domestic business consulting Tel:+86-731-85714218
E-mail:yingxiao@qankorey.com
Internation Marketing Tel:+86-18874232226
E-mail:lisa@qankorey.com
Company address: 12F, Building 15, No.188 Middle Huanbao Road, Yuhua District, Changsha, Hunan, China 410116
Production Address: 4/F, Building 7, Yuhua Intelligent Manufacturing Center, No.2 Hongda Road, Tongsheng Street, Yuhua District, Changsha,Hunan China,410007
Public Number
Small program
Jingdong
Taobao